 Whitney High
Concepts (371)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 15 | 2020 | 762 | 2.540 |
Why?
| | Melanoma | 13 | 2020 | 664 | 2.480 |
Why?
| | Skin Diseases | 10 | 2013 | 125 | 2.210 |
Why?
| | Dermatology | 5 | 2013 | 88 | 1.470 |
Why?
| | Skin Diseases, Vesiculobullous | 4 | 2011 | 17 | 1.360 |
Why?
| | Immunohistochemistry | 14 | 2020 | 1691 | 1.190 |
Why?
| | Nephrogenic Fibrosing Dermopathy | 6 | 2012 | 8 | 1.110 |
Why?
| | Nevus, Pigmented | 4 | 2020 | 33 | 1.040 |
Why?
| | Gadolinium DTPA | 6 | 2012 | 54 | 0.990 |
Why?
| | Bedbugs | 2 | 2017 | 2 | 0.960 |
Why?
| | Contrast Media | 9 | 2012 | 373 | 0.890 |
Why?
| | Malpractice | 3 | 2013 | 38 | 0.850 |
Why?
| | Skin | 11 | 2011 | 657 | 0.850 |
Why?
| | Lupus Erythematosus, Cutaneous | 3 | 2007 | 6 | 0.810 |
Why?
| | Gadolinium | 4 | 2010 | 79 | 0.810 |
Why?
| | Dermatitis, Allergic Contact | 3 | 2006 | 60 | 0.720 |
Why?
| | Psoriasis | 3 | 2013 | 76 | 0.660 |
Why?
| | Kidney Failure, Chronic | 3 | 2009 | 516 | 0.650 |
Why?
| | Skin Ulcer | 1 | 2018 | 15 | 0.640 |
Why?
| | Seminoma | 1 | 2018 | 17 | 0.630 |
Why?
| | Histiocytosis, Langerhans-Cell | 2 | 2008 | 35 | 0.630 |
Why?
| | Ectoparasitic Infestations | 1 | 2017 | 3 | 0.600 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2018 | 60 | 0.590 |
Why?
| | Testicular Neoplasms | 1 | 2018 | 95 | 0.570 |
Why?
| | Dermatitis, Atopic | 3 | 2013 | 332 | 0.570 |
Why?
| | Erythema | 3 | 2009 | 24 | 0.550 |
Why?
| | Scrotum | 2 | 2018 | 25 | 0.550 |
Why?
| | Nail Diseases | 2 | 2006 | 4 | 0.540 |
Why?
| | Fibrosis | 6 | 2008 | 483 | 0.510 |
Why?
| | Humans | 68 | 2021 | 119032 | 0.500 |
Why?
| | Medicare | 1 | 2020 | 665 | 0.500 |
Why?
| | Neurothekeoma | 1 | 2014 | 4 | 0.490 |
Why?
| | Defensive Medicine | 1 | 2013 | 2 | 0.480 |
Why?
| | Telepathology | 1 | 2013 | 3 | 0.480 |
Why?
| | Licensure | 1 | 2013 | 10 | 0.480 |
Why?
| | Antibodies, Monoclonal | 3 | 2014 | 1285 | 0.470 |
Why?
| | Diagnostic Errors | 2 | 2012 | 162 | 0.470 |
Why?
| | Lupus Erythematosus, Discoid | 2 | 2015 | 7 | 0.410 |
Why?
| | Scabies | 1 | 2011 | 1 | 0.410 |
Why?
| | Elephantiasis | 1 | 2011 | 3 | 0.400 |
Why?
| | Hidradenitis Suppurativa | 1 | 2011 | 9 | 0.400 |
Why?
| | Genital Diseases, Male | 1 | 2011 | 15 | 0.400 |
Why?
| | Ganglion Cysts | 1 | 2011 | 10 | 0.400 |
Why?
| | Acromioclavicular Joint | 1 | 2011 | 16 | 0.400 |
Why?
| | Male | 37 | 2020 | 57818 | 0.400 |
Why?
| | Biopsy | 7 | 2021 | 1079 | 0.370 |
Why?
| | Piperazines | 2 | 2012 | 316 | 0.370 |
Why?
| | Insect Bites and Stings | 1 | 2009 | 12 | 0.350 |
Why?
| | Pyrimidines | 2 | 2012 | 382 | 0.350 |
Why?
| | Adult | 28 | 2020 | 31525 | 0.350 |
Why?
| | Diagnosis, Differential | 9 | 2015 | 1384 | 0.340 |
Why?
| | Cocaine | 2 | 2012 | 158 | 0.340 |
Why?
| | Biomarkers, Tumor | 4 | 2020 | 1059 | 0.340 |
Why?
| | Keratoacanthoma | 1 | 2008 | 3 | 0.340 |
Why?
| | Keratolytic Agents | 1 | 2008 | 5 | 0.340 |
Why?
| | Spectrometry, Fluorescence | 1 | 2009 | 173 | 0.340 |
Why?
| | Isotretinoin | 1 | 2008 | 22 | 0.340 |
Why?
| | Antineoplastic Agents | 3 | 2010 | 1974 | 0.340 |
Why?
| | Female | 36 | 2020 | 61588 | 0.330 |
Why?
| | Syphilis | 2 | 2005 | 26 | 0.330 |
Why?
| | Hypersensitivity, Delayed | 1 | 2008 | 52 | 0.330 |
Why?
| | Pyroglyphidae | 1 | 2008 | 17 | 0.330 |
Why?
| | Pathology, Clinical | 1 | 2008 | 31 | 0.320 |
Why?
| | Sweet Syndrome | 1 | 2007 | 8 | 0.320 |
Why?
| | Middle Aged | 23 | 2020 | 27627 | 0.310 |
Why?
| | Scleroderma, Systemic | 1 | 2008 | 94 | 0.310 |
Why?
| | Aged | 20 | 2021 | 19661 | 0.310 |
Why?
| | Skin Diseases, Infectious | 1 | 2007 | 16 | 0.300 |
Why?
| | Dermatomyositis | 2 | 2004 | 22 | 0.300 |
Why?
| | Alopecia | 2 | 2013 | 34 | 0.290 |
Why?
| | Kidney Diseases | 2 | 2008 | 442 | 0.290 |
Why?
| | Body Piercing | 1 | 2006 | 4 | 0.290 |
Why?
| | Antibodies, Antinuclear | 2 | 2004 | 55 | 0.290 |
Why?
| | Histiocytoma | 1 | 2006 | 2 | 0.290 |
Why?
| | Hemangiopericytoma | 1 | 2006 | 3 | 0.290 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 29 | 0.290 |
Why?
| | Epithelioid Cells | 1 | 2006 | 8 | 0.290 |
Why?
| | Communicable Diseases, Emerging | 1 | 2007 | 28 | 0.290 |
Why?
| | Granuloma, Pyogenic | 1 | 2006 | 6 | 0.290 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2007 | 41 | 0.290 |
Why?
| | Dermatitis, Seborrheic | 1 | 2006 | 4 | 0.290 |
Why?
| | Exanthema | 1 | 2007 | 77 | 0.280 |
Why?
| | Granuloma | 1 | 2006 | 87 | 0.280 |
Why?
| | Titanium | 1 | 2006 | 67 | 0.280 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2007 | 73 | 0.270 |
Why?
| | Hyperkeratosis, Epidermolytic | 1 | 2005 | 19 | 0.270 |
Why?
| | Neoplasm Regression, Spontaneous | 1 | 2005 | 3 | 0.270 |
Why?
| | Genital Diseases, Female | 1 | 2005 | 28 | 0.270 |
Why?
| | Scalp | 1 | 2005 | 29 | 0.260 |
Why?
| | Telemedicine | 1 | 2013 | 668 | 0.260 |
Why?
| | Tacrolimus | 1 | 2006 | 151 | 0.260 |
Why?
| | Ossification, Heterotopic | 1 | 2004 | 15 | 0.260 |
Why?
| | Ear, External | 1 | 2004 | 24 | 0.260 |
Why?
| | Ear Diseases | 1 | 2004 | 14 | 0.250 |
Why?
| | Quinazolines | 1 | 2006 | 245 | 0.250 |
Why?
| | Tuberculosis, Miliary | 1 | 2004 | 5 | 0.250 |
Why?
| | Tuberculosis, Cutaneous | 1 | 2004 | 4 | 0.250 |
Why?
| | Allergens | 1 | 2008 | 425 | 0.250 |
Why?
| | Agave | 1 | 2003 | 1 | 0.240 |
Why?
| | Fibroma | 1 | 2004 | 20 | 0.240 |
Why?
| | Biopsy, Needle | 5 | 2011 | 190 | 0.240 |
Why?
| | Protein Kinase Inhibitors | 2 | 2012 | 811 | 0.230 |
Why?
| | Alendronate | 1 | 2003 | 7 | 0.230 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2010 | 610 | 0.230 |
Why?
| | Tumor Virus Infections | 1 | 2003 | 41 | 0.230 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 304 | 0.230 |
Why?
| | Women's Health | 1 | 2005 | 274 | 0.230 |
Why?
| | Facial Dermatoses | 1 | 2003 | 14 | 0.230 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2004 | 113 | 0.230 |
Why?
| | Hyperpigmentation | 1 | 2003 | 11 | 0.230 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 462 | 0.230 |
Why?
| | Vasculitis | 1 | 2003 | 75 | 0.220 |
Why?
| | Papillomaviridae | 1 | 2003 | 101 | 0.220 |
Why?
| | United States | 7 | 2020 | 12557 | 0.220 |
Why?
| | Cicatrix | 1 | 2003 | 53 | 0.220 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 307 | 0.220 |
Why?
| | Pregnancy Outcome | 1 | 2005 | 349 | 0.220 |
Why?
| | Antirheumatic Agents | 1 | 2005 | 254 | 0.220 |
Why?
| | Prognosis | 5 | 2017 | 3443 | 0.210 |
Why?
| | Cheilitis | 1 | 2021 | 3 | 0.210 |
Why?
| | Patch Tests | 3 | 2008 | 50 | 0.200 |
Why?
| | Pulmonary Fibrosis | 1 | 2003 | 303 | 0.190 |
Why?
| | Cannabis | 1 | 2007 | 382 | 0.190 |
Why?
| | Genetic Testing | 2 | 2017 | 389 | 0.190 |
Why?
| | Pregnancy Complications | 1 | 2005 | 448 | 0.190 |
Why?
| | MART-1 Antigen | 1 | 2020 | 9 | 0.190 |
Why?
| | Aged, 80 and over | 8 | 2015 | 6562 | 0.180 |
Why?
| | SOXE Transcription Factors | 1 | 2020 | 17 | 0.180 |
Why?
| | Papillomavirus Infections | 1 | 2003 | 265 | 0.180 |
Why?
| | Benzamides | 2 | 2012 | 176 | 0.180 |
Why?
| | Societies, Medical | 1 | 2003 | 703 | 0.180 |
Why?
| | HIV Infections | 2 | 2004 | 2461 | 0.170 |
Why?
| | Head and Neck Neoplasms | 2 | 2019 | 471 | 0.170 |
Why?
| | Retrospective Studies | 8 | 2020 | 12990 | 0.170 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 239 | 0.160 |
Why?
| | Methotrexate | 3 | 2012 | 227 | 0.160 |
Why?
| | Dermoscopy | 2 | 2017 | 9 | 0.160 |
Why?
| | Comparative Genomic Hybridization | 1 | 2017 | 28 | 0.150 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2019 | 299 | 0.150 |
Why?
| | Lip | 2 | 2021 | 20 | 0.150 |
Why?
| | Pruritus | 2 | 2009 | 60 | 0.150 |
Why?
| | STAT3 Transcription Factor | 1 | 2019 | 189 | 0.150 |
Why?
| | Bites and Stings | 1 | 2017 | 31 | 0.150 |
Why?
| | Severity of Illness Index | 4 | 2009 | 2674 | 0.150 |
Why?
| | Tumor Suppressor Proteins | 1 | 2019 | 289 | 0.150 |
Why?
| | Risk Assessment | 5 | 2011 | 3057 | 0.140 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2017 | 311 | 0.140 |
Why?
| | Dermatologic Agents | 2 | 2013 | 57 | 0.140 |
Why?
| | Lichenoid Eruptions | 1 | 2015 | 3 | 0.140 |
Why?
| | Mutation | 1 | 2007 | 3457 | 0.140 |
Why?
| | Sampling Studies | 2 | 2007 | 92 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 4 | 2011 | 3175 | 0.130 |
Why?
| | Child, Preschool | 4 | 2014 | 9493 | 0.130 |
Why?
| | Child | 6 | 2014 | 19137 | 0.130 |
Why?
| | Renal Dialysis | 2 | 2009 | 378 | 0.130 |
Why?
| | Follow-Up Studies | 4 | 2011 | 4596 | 0.130 |
Why?
| | Mass Spectrometry | 2 | 2008 | 681 | 0.120 |
Why?
| | Animals | 8 | 2019 | 33399 | 0.120 |
Why?
| | Face | 1 | 2015 | 165 | 0.120 |
Why?
| | Insurance, Liability | 1 | 2013 | 6 | 0.120 |
Why?
| | Mohs Surgery | 2 | 2004 | 25 | 0.120 |
Why?
| | Internship and Residency | 1 | 2003 | 1006 | 0.120 |
Why?
| | Liability, Legal | 1 | 2013 | 39 | 0.120 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1597 | 0.110 |
Why?
| | Photography | 1 | 2013 | 93 | 0.110 |
Why?
| | Antinematodal Agents | 1 | 2012 | 5 | 0.110 |
Why?
| | Imatinib Mesylate | 2 | 2012 | 64 | 0.110 |
Why?
| | Immunosuppressive Agents | 2 | 2009 | 683 | 0.110 |
Why?
| | Fetal Diseases | 1 | 2013 | 148 | 0.110 |
Why?
| | Levamisole | 1 | 2012 | 20 | 0.110 |
Why?
| | Drug Contamination | 1 | 2012 | 54 | 0.110 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2012 | 43 | 0.100 |
Why?
| | Argyria | 1 | 2011 | 4 | 0.100 |
Why?
| | Carcinoma, Basal Cell | 2 | 2010 | 67 | 0.100 |
Why?
| | Pilot Projects | 2 | 2006 | 1420 | 0.100 |
Why?
| | Orphanages | 1 | 2011 | 2 | 0.100 |
Why?
| | Granuloma, Foreign-Body | 1 | 2011 | 10 | 0.100 |
Why?
| | Vietnam | 1 | 2011 | 22 | 0.100 |
Why?
| | Ethiopia | 1 | 2011 | 35 | 0.100 |
Why?
| | Durapatite | 1 | 2011 | 33 | 0.100 |
Why?
| | Synovial Fluid | 1 | 2011 | 56 | 0.100 |
Why?
| | Foreign-Body Migration | 1 | 2011 | 37 | 0.100 |
Why?
| | Adoption | 1 | 2011 | 38 | 0.100 |
Why?
| | Cocaine-Related Disorders | 1 | 2012 | 107 | 0.100 |
Why?
| | Mucins | 1 | 2011 | 59 | 0.100 |
Why?
| | Rupture | 1 | 2011 | 105 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2012 | 9346 | 0.100 |
Why?
| | Sensitivity and Specificity | 3 | 2020 | 1795 | 0.100 |
Why?
| | Transcription Factors | 1 | 2019 | 1570 | 0.100 |
Why?
| | China | 1 | 2011 | 175 | 0.100 |
Why?
| | Rotator Cuff Injuries | 1 | 2011 | 61 | 0.100 |
Why?
| | Adolescent | 5 | 2014 | 18483 | 0.090 |
Why?
| | Aminolevulinic Acid | 1 | 2010 | 2 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2018 | 1753 | 0.090 |
Why?
| | Injections, Intralesional | 1 | 2010 | 33 | 0.090 |
Why?
| | Health Care Costs | 1 | 2013 | 394 | 0.090 |
Why?
| | Practice Guidelines as Topic | 2 | 2008 | 1440 | 0.090 |
Why?
| | Eccrine Glands | 1 | 2009 | 2 | 0.090 |
Why?
| | Guatemala | 1 | 2011 | 296 | 0.090 |
Why?
| | Synchrotrons | 1 | 2009 | 9 | 0.090 |
Why?
| | Photopheresis | 1 | 2009 | 9 | 0.090 |
Why?
| | Iron-Dextran Complex | 1 | 2009 | 10 | 0.090 |
Why?
| | Algorithms | 1 | 2017 | 1543 | 0.090 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 82 | 0.090 |
Why?
| | Plasmapheresis | 1 | 2009 | 23 | 0.090 |
Why?
| | Arthropod Vectors | 1 | 2009 | 7 | 0.090 |
Why?
| | Observation | 1 | 2009 | 50 | 0.090 |
Why?
| | Ultraviolet Therapy | 1 | 2009 | 20 | 0.090 |
Why?
| | Bedding and Linens | 1 | 2009 | 9 | 0.090 |
Why?
| | Hyaluronic Acid | 1 | 2011 | 197 | 0.090 |
Why?
| | Naphthoquinones | 1 | 2009 | 18 | 0.090 |
Why?
| | Fluorouracil | 1 | 2010 | 151 | 0.090 |
Why?
| | Rituximab | 1 | 2010 | 155 | 0.090 |
Why?
| | Lymphoma, B-Cell | 1 | 2010 | 85 | 0.090 |
Why?
| | Erythropoietin | 1 | 2009 | 82 | 0.080 |
Why?
| | Interferon-alpha | 1 | 2010 | 191 | 0.080 |
Why?
| | Interleukin-2 | 1 | 2010 | 417 | 0.080 |
Why?
| | Histiocytes | 1 | 2008 | 5 | 0.080 |
Why?
| | Bleomycin | 1 | 2010 | 228 | 0.080 |
Why?
| | Histiocytosis | 1 | 2008 | 8 | 0.080 |
Why?
| | Langerhans Cells | 1 | 2008 | 11 | 0.080 |
Why?
| | Diabetes Insipidus | 1 | 2008 | 7 | 0.080 |
Why?
| | Vitiligo | 1 | 2009 | 75 | 0.080 |
Why?
| | Carcinoma, Skin Appendage | 1 | 2007 | 2 | 0.080 |
Why?
| | Failure to Thrive | 1 | 2008 | 31 | 0.080 |
Why?
| | Prednisone | 2 | 2012 | 235 | 0.080 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 544 | 0.080 |
Why?
| | Antigen-Presenting Cells | 1 | 2008 | 156 | 0.080 |
Why?
| | Imidazoles | 1 | 2009 | 232 | 0.080 |
Why?
| | Microtubule-Associated Proteins | 1 | 2009 | 188 | 0.080 |
Why?
| | Medical Records | 1 | 2008 | 163 | 0.080 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2008 | 130 | 0.080 |
Why?
| | Bone Diseases | 1 | 2008 | 59 | 0.080 |
Why?
| | Risk Management | 1 | 2008 | 90 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2020 | 3173 | 0.080 |
Why?
| | Amoeba | 1 | 2007 | 1 | 0.080 |
Why?
| | Gnathostoma | 1 | 2007 | 1 | 0.080 |
Why?
| | Pythium | 1 | 2007 | 1 | 0.080 |
Why?
| | Spirurida Infections | 1 | 2007 | 1 | 0.080 |
Why?
| | Pregnancy | 3 | 2013 | 5694 | 0.070 |
Why?
| | Amebiasis | 1 | 2007 | 5 | 0.070 |
Why?
| | Penicillium | 1 | 2007 | 6 | 0.070 |
Why?
| | Keratinocytes | 1 | 2008 | 227 | 0.070 |
Why?
| | Genes, p16 | 1 | 2007 | 18 | 0.070 |
Why?
| | Electron Probe Microanalysis | 1 | 2006 | 3 | 0.070 |
Why?
| | Microphthalmia-Associated Transcription Factor | 1 | 2007 | 14 | 0.070 |
Why?
| | Receptor, Melanocortin, Type 1 | 1 | 2007 | 24 | 0.070 |
Why?
| | Skull | 1 | 2008 | 127 | 0.070 |
Why?
| | Paraffin Embedding | 1 | 2006 | 22 | 0.070 |
Why?
| | Epidermis | 1 | 2007 | 152 | 0.070 |
Why?
| | Subcutaneous Tissue | 1 | 2006 | 17 | 0.070 |
Why?
| | Factor XIIIa | 1 | 2006 | 5 | 0.070 |
Why?
| | Hypopigmentation | 1 | 2006 | 2 | 0.070 |
Why?
| | Dermis | 1 | 2006 | 29 | 0.070 |
Why?
| | Dosage Forms | 1 | 2006 | 11 | 0.070 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 12 | 0.070 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2006 | 196 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1167 | 0.070 |
Why?
| | Diabetic Nephropathies | 1 | 2009 | 289 | 0.070 |
Why?
| | Organ Specificity | 1 | 2006 | 278 | 0.070 |
Why?
| | Lysosomes | 1 | 2006 | 136 | 0.070 |
Why?
| | Single-Blind Method | 1 | 2006 | 269 | 0.070 |
Why?
| | Metals | 1 | 2006 | 111 | 0.070 |
Why?
| | Tissue Distribution | 1 | 2006 | 334 | 0.070 |
Why?
| | PTEN Phosphohydrolase | 1 | 2007 | 143 | 0.070 |
Why?
| | Signal Transduction | 1 | 2019 | 4713 | 0.070 |
Why?
| | Acidosis | 1 | 2006 | 86 | 0.070 |
Why?
| | Viscera | 1 | 2005 | 16 | 0.070 |
Why?
| | Mitosis | 1 | 2006 | 172 | 0.070 |
Why?
| | Pregnancy, Multiple | 1 | 2005 | 19 | 0.070 |
Why?
| | Remission, Spontaneous | 1 | 2005 | 37 | 0.070 |
Why?
| | Pregnancy Trimester, Third | 1 | 2005 | 69 | 0.070 |
Why?
| | Radiography | 1 | 2008 | 861 | 0.060 |
Why?
| | Knee Joint | 1 | 2008 | 353 | 0.060 |
Why?
| | Foot | 1 | 2005 | 106 | 0.060 |
Why?
| | Treponema pallidum | 1 | 2004 | 7 | 0.060 |
Why?
| | Iron | 1 | 2006 | 248 | 0.060 |
Why?
| | Rare Diseases | 1 | 2005 | 113 | 0.060 |
Why?
| | Infliximab | 1 | 2005 | 94 | 0.060 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2007 | 202 | 0.060 |
Why?
| | Urticaria | 1 | 2005 | 51 | 0.060 |
Why?
| | Renal Insufficiency | 1 | 2006 | 150 | 0.060 |
Why?
| | Sclerosis | 1 | 2004 | 14 | 0.060 |
Why?
| | Infant, Newborn | 2 | 2007 | 5256 | 0.060 |
Why?
| | Hand | 1 | 2005 | 137 | 0.060 |
Why?
| | Infant | 2 | 2008 | 8295 | 0.060 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2007 | 317 | 0.060 |
Why?
| | Glucocorticoids | 2 | 2012 | 547 | 0.060 |
Why?
| | Infusions, Intravenous | 1 | 2005 | 380 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1167 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2010 | 585 | 0.060 |
Why?
| | Nails | 1 | 2003 | 10 | 0.060 |
Why?
| | Staining and Labeling | 1 | 2004 | 146 | 0.060 |
Why?
| | Chest Pain | 1 | 2004 | 84 | 0.060 |
Why?
| | Twins | 1 | 2005 | 247 | 0.060 |
Why?
| | Cell Nucleus | 1 | 2006 | 580 | 0.060 |
Why?
| | Quality of Health Care | 1 | 2008 | 586 | 0.060 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2009 | 590 | 0.060 |
Why?
| | Arm | 1 | 2003 | 106 | 0.060 |
Why?
| | Cell Cycle Proteins | 1 | 2007 | 565 | 0.060 |
Why?
| | Plant Leaves | 1 | 2003 | 118 | 0.060 |
Why?
| | Atrophy | 1 | 2003 | 164 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2003 | 287 | 0.050 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2006 | 455 | 0.050 |
Why?
| | Young Adult | 2 | 2015 | 10799 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 827 | 0.050 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2004 | 227 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2005 | 521 | 0.050 |
Why?
| | Coronary Disease | 1 | 2004 | 356 | 0.050 |
Why?
| | Plasma Cells | 1 | 2021 | 59 | 0.050 |
Why?
| | Blotting, Western | 1 | 2004 | 1195 | 0.050 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1223 | 0.050 |
Why?
| | Age Factors | 1 | 2008 | 2995 | 0.050 |
Why?
| | Cohort Studies | 2 | 2008 | 5117 | 0.050 |
Why?
| | Osteoporosis | 1 | 2003 | 229 | 0.050 |
Why?
| | Rats, Wistar | 2 | 2012 | 399 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1390 | 0.040 |
Why?
| | Respiratory Insufficiency | 1 | 2003 | 290 | 0.040 |
Why?
| | Kidney | 1 | 2007 | 1357 | 0.040 |
Why?
| | Genotype | 1 | 2003 | 1882 | 0.040 |
Why?
| | Risk Factors | 2 | 2009 | 9003 | 0.040 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 968 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2275 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 982 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2019 | 182 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 663 | 0.040 |
Why?
| | Clinical Competence | 1 | 2003 | 951 | 0.040 |
Why?
| | Arthritis, Rheumatoid | 1 | 2005 | 990 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2020 | 360 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 277 | 0.030 |
Why?
| | Minoxidil | 1 | 2013 | 1 | 0.030 |
Why?
| | Retinoids | 1 | 2013 | 32 | 0.030 |
Why?
| | Acne Vulgaris | 1 | 2013 | 20 | 0.030 |
Why?
| | Hydroxychloroquine | 1 | 2013 | 59 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2006 | 2220 | 0.030 |
Why?
| | Inflammation | 1 | 2004 | 2571 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2003 | 4552 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2004 | 1864 | 0.030 |
Why?
| | Rats | 2 | 2012 | 5394 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 2851 | 0.030 |
Why?
| | Injections, Intradermal | 1 | 2011 | 11 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 4709 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 2490 | 0.030 |
Why?
| | Transcriptome | 1 | 2017 | 756 | 0.030 |
Why?
| | Cosmetic Techniques | 1 | 2011 | 13 | 0.030 |
Why?
| | Microscopy, Electron | 1 | 2011 | 413 | 0.020 |
Why?
| | Epoetin Alfa | 1 | 2009 | 6 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2009 | 210 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 965 | 0.020 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2009 | 44 | 0.020 |
Why?
| | Drug Synergism | 1 | 2009 | 339 | 0.020 |
Why?
| | Keratin-15 | 1 | 2007 | 14 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 247 | 0.020 |
Why?
| | Axilla | 1 | 2006 | 57 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1125 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1308 | 0.020 |
Why?
| | Databases, Factual | 1 | 2010 | 1231 | 0.020 |
Why?
| | Silver Staining | 1 | 2004 | 19 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 1947 | 0.020 |
Why?
| | Echocardiography, Stress | 1 | 2004 | 21 | 0.020 |
Why?
| | Incidence | 1 | 2010 | 2424 | 0.010 |
Why?
| | Causality | 1 | 2004 | 109 | 0.010 |
Why?
| | Calcium | 1 | 2009 | 1171 | 0.010 |
Why?
| | Mice | 1 | 2019 | 15528 | 0.010 |
Why?
| | Gastrointestinal Diseases | 1 | 2004 | 187 | 0.010 |
Why?
| | Electroencephalography | 1 | 2004 | 387 | 0.010 |
Why?
| | Exercise Test | 1 | 2004 | 551 | 0.010 |
Why?
| | Acute Disease | 1 | 2004 | 941 | 0.010 |
Why?
| | Recurrence | 1 | 2004 | 975 | 0.010 |
Why?
| | Survival Analysis | 1 | 2004 | 1267 | 0.010 |
Why?
| | Hospitalization | 1 | 2004 | 1785 | 0.010 |
Why?
|
|
High's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|